Lipoic acid plays a role in scleroderma: Insights obtained from scleroderma dermal fibroblasts

Arthritis Research and Therapy

Volumn 16, Issue 4, 2015, Pages

  Tsou, Pei Suen ^a,b   Balogh, Beatrix ^b   Pinney, Adam J ^b   Zakhem, George ^b   Lozier, Ann ^b   Amin, M Asif ^b   Stinson, William A ^b   Schiopu, Elena ^a,b   Khanna, Dinesh ^a,b   Fox, David A ^b   Koch, Alisa E ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84938290515     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0411-6     Document Type: Article

References (63)

1. Tsou PS, Talia NN, Pinney AJ, Kendzicky A, Piera-Velazquez S, Jimenez SA, Seibold JR, Phillips K, Koch AE: Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts. Arthritis Rheum 2012, 64:1978-1989.
2. Gabrielli A, Svegliati S, Moroncini G, Amico D: New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J 2012, 6:87-95.
3. Allanore Y, Borderie D, Lemaréchal H, Ekindjian OG, Kahan A: Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004, 116:595-600.
4. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, Sato S: Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford) 2006, 45:815-818.
5. Servettaz A, Guilpain P, Goulvestre C, Chereau C, Hercend C, Nicco C, Guillevin L, Weill B, Mouthon L, Batteux F: Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 2007, 66:1202-1209.
6. Sfrent-Cornateanu R, Mihai C, Stoian I, Lixandru D, Bara C, Moldoveanu E: Antioxidant defense capacity in scleroderma patients. Clin Chem Lab Med 2008, 46:836-841.
7. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI: Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994, 21:1477-1483.
8. Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K, Bruckdorfer KR, Black CM: Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology (Oxford) 1999, 38:309-315.
9. Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K, Moore T, Braganza JM, Jayson MI: A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 2000, 18:349-356.
10. Allanore Y, Borderie D, Périanin A, Lemaréchal H, Ekindjian OG, Kahan A: Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Res Ther 2005, 7:R93-R100.
11. Galbusera C, Orth P, Fedida D, Spector T: Superoxide radical production by allopurinol and xanthine oxidase. Biochem Pharmacol 2006, 71:1747-1752.
12. Firuzi O, Fuksa L, Spadaro C, Bousova I, Riccieri V, Spadaro A, Petrucci R, Marrosu G, Saso L: Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol 2006, 58:951-957.
13. 2 NQ prevents HOCl-induced systemic sclerosis in mouse. J Invest Dermatol 2012, 132:1125-1132.
14. Kagan VE, Serbinova EA, Forte T, Scita G, Packer L: Recycling of vitamin E in human low density lipoproteins. J Lipid Res 1992, 33:385-397.
15. Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu RM, Hagen TM: Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci U S A 2004, 101:3381-3386.
16. Rosato E, Cianci R, Barbano B, Menghi G, Gigante A, Rossi C, Zardi EM, Amoroso A, Pisarri S, Salsano F: N -acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis. Acta Pharmacol Sin 2009, 30:1283-1288.
17. Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, Gabrielli A: Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001, 28:2257-2262.
18. Yildirim Z, Kotuk M, Iraz M, Kuku I, Ulu R, Armutcu F, Ozen S: Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: erdosteine and N -acetylcysteine. Pulm Pharmacol Ther 2005, 18:367-373.
19. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
20. Ruth JH, Arendt MD, Amin MA, Ahmed S, Marotte H, Rabquer BJ, Lesch C, Lee S, Koch AE: Expression and function of CXCL16 in a novel model of gout. Arthritis Rheum 2010, 62:2536-2544.
21. Failli P, Palmieri L, D'Alfonso C, Giovannelli L, Generini S, Rosso AD, Pignone A, Stanflin N, Orsi S, Zilletti L, Matucci-Cerinic M: Effect of N -acetyl-L-cysteine on peroxynitrite and superoxide anion production of lung alveolar macrophages in systemic sclerosis. Nitric Oxide 2002, 7:277-282.
22. Rosato E, Borghese F, Pisarri S, Salsano F: The treatment with N -acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol 2009, 28:1379-1384.
23. Shi-wen X, Thompson K, Khan K, Liu S, Murphy-Marshman H, Baron M, Denton CP, Leask A, Abraham DJ: Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology (Oxford) 2012, 51:2146-2154.
24. Hermann R, Niebch G, Borbe HO, Fieger-Büschges H, Ruus P, Nowak H, Riethmüller-Winzen H, Peukert M, Blume H: Enantioselective pharmacokinetics and bioavailability of different racemic aα-lipoic acid formulations in healthy volunteers. Eur J Pharm Sci 1996, 4:167-174.
25. Olsson B, Johansson M, Gabrielsson J, Bolme P: Pharmacokinetics and bioavailability of reduced and oxidized N -acetylcysteine. Eur J Clin Pharmacol 1988, 34:77-82.
26. Teichert J, Preiss R: [17] High-performance liquid chromatography methods for determination of lipoic and dihydrolipoic acid in human plasma. Methods Enzymol 1997, 279:159-166.
27. Khan A, Iqbal Z, Watson DG, Khan A, Khan I, Muhammad N, Muhammad S, Nasib HA, Iqbal N, Faiz-ur-rahman, Kashif M: Simultaneous determination of lipoic acid (LA) and dihydrolipoic acid (DHLA) in human plasma using high-performance liquid chromatography coupled with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:1725-1731.
28. Michelet F, Gueguen R, Leroy P, Wellman M, Nicolas A, Siest G: Blood and plasma glutathione measured in healthy subjects by HPLC: relation to sex, aging, biological variables, and life habits. Clin Chem 1995, 41:1509-1517.
29. Hultberg B, Andersson A, Isaksson A: Lipoic acid increases glutathione production and enhances the effect of mercury in human cell lines. Toxicology 2002, 175:103-110.
30. Krishnan CV, Garnett M: Electrochemical behavior of the super antioxidant, aα-lipoic acid. Int J Electrochem Sci 2011, 6:3607-3630.
31. Liu R, Ahmed KM, Nantajit D, Rosenthal FS, Hai CX, Li JJ: Therapeutic effects of aα-lipoic acid on bleomycin-induced pulmonary fibrosis in rats. Int J Mol Med 2007, 19:865-873.
32. Lee JE, Yi CO, Jeon BT, Shin HJ, Kim SK, Jung TS, Choi JY, Roh GS: aα-Lipoic acid attenuates cardiac fibrosis in Otsuka Long-Evans Tokushima fatty rats. Cardiovasc Diabetol 2012, 11:111.
33. Li CJ, Lv L, Li H, Yu DM: Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by aα-lipoic acid. Cardiovasc Diabetol 2012, 11:73.
34. Foo NP, Lin SH, Lee YH, Wu MJ, Wang YJ: aα-Lipoic acid inhibits liver fibrosis through the attenuation of ROS-triggered signaling in hepatic stellate cells activated by PDGF and TGF-β. Toxicology 2011, 282:39-46.
35. Min AK, Kim MK, Seo HY, Kim HS, Jang BK, Hwang JS, Choi HS, Lee KU, Park KG, Lee IK: aα-lipoic acid inhibits hepatic PAI-1 expression and fibrosis by inhibiting the TGF-β signaling pathway. Biochem Biophys Res Commun 2010, 393:536-541.
36. Budisavljevic MN, Hodge L, Barber K, Fulmer JR, Durazo-Arvizu RA, Self SE, Kuhlmann M, Raymond JR, Greene EL: Oxidative stress in the pathogenesis of experimental mesangial proliferative glomerulonephritis. Am J Physiol Renal Physiol 2003, 285:F1138-F1148.
37. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, ten Dijke P, White B, Wigley FM, Goldschmidt-Clermont PJ: Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 2002, 99:3908-3913.
38. Wei J, Ghosh AK, Sargent JL, Komura K, Wu M, Huang QQ, Jain M, Whitfield ML, Feghali-Bostwick C, Varga J: PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010, 5:e13778.
39. Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM: Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 1998, 31:S360-S363.
40. Giannelli G, Iannone F, Marinosci F, Lapadula G, Antonaci S: The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin 2005, 21:327-332.
41. Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD: Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem 1995, 270:3423-3428.
42. Bond M, Baker AH, Newby AC: Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999, 264:561-567.
43. Shin MH, Moon YJ, Seo JE, Lee Y, Kim KH, Chung JH: Reactive oxygen species produced by NADPH oxidase, xanthine oxidase, and mitochondrial electron transport system mediate heat shock-induced MMP-1 and MMP-9 expression. Free Radic Biol Med 2008, 44:635-645.
44. Kar S, Subbaram S, Carrico PM, Melendez JA: Redox-control of matrix metalloproteinase-1: a critical link between free radicals, matrix remodeling and degenerative disease. Respir Physiol Neurobiol 2010, 174:299-306.
45. Sato H, Seiki M: Regulatory mechanism of 92kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993, 8:395-405.
46. Bond M, Chase AJ, Baker AH, Newby AC: Inhibition of transcription factor NF-κB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res 2001, 50:556-565.
47. Simon C, Simon M, Vucelic G, Hicks MJ, Plinkert PK, Koitschev A, Zenner HP: The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exp Cell Res 2001, 271:344-355.
48. Kim HS, Kim HJ, Park KG, Kim YN, Kwon TK, Park JY, Lee KU, Kim JG, Lee IK: aα-Lipoic acid inhibits matrix metalloproteinase-9 expression by inhibiting NF-κB transcriptional activity. Exp Mol Med 2007, 39:106-113.
49. Uchijima M, Sato H, Fujii M, Seiki M: Tax proteins of human T-cell leukemia virus type 1 and 2 induce expression of the gene encoding erythroid-potentiating activity (tissue inhibitor of metalloproteinases-1, TIMP-1). J Biol Chem 1994, 269:14946-14950.
50. Campbell CE, Flenniken AM, Skup D, Williams BR: Identification of a serum- and phorbol ester-responsive element in the murine tissue inhibitor of metalloproteinase gene. J Biol Chem 1991, 266:7199-7206.
51. Edwards DR, Rocheleau H, Sharma RR, Wills AJ, Cowie A, Hassell JA, Heath JK: Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. Biochim Biophys Acta 1992, 1171:41-55.
52. Logan SK, Garabedian MJ, Campbell CE, Werb Z: Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors. J Biol Chem 1996, 271:774-782.
53. Kwak HJ, Park MJ, Cho H, Park CM, Moon SI, Lee HC, Park IC, Kim MS, Rhee CH, Hong SI: Transforming growth factor-β1 induces tissue inhibitor of metalloproteinase-1 expression via activation of extracellular signal-regulated kinase and Sp1 in human fibrosarcoma cells. Mol Cancer Res 2006, 4:209-220.
54. Sen CK, Packer L: Antioxidant and redox regulation of gene transcription. FASEB J 1996, 10:709-720.
55. Packer L: aα-Lipoic acid: a metabolic antioxidant which regulates NF-κB signal transduction and protects against oxidative injury. Drug Metab Rev 1998, 30:245-275.
56. Zhang WJ, Frei B: aα-Lipoic acid inhibits TNF-aα-induced NF-κB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001, 15:2423-2432.
57. Pinkus R, Bergelson S, Daniel V: Phenobarbital induction of AP-1 binding activity mediates activation of glutathione S -transferase and quinone reductase gene expression. Biochem J 1993, 290:637-640.
58. Keyse SM, Emslie EA: Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature 1992, 359:644-647.
59. Denu JM, Tanner KG: Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 1998, 37:5633-5642.
60. Meng TC, Fukada T, Tonks NK: Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002, 9:387-399.
61. Parsons ZD, Gates KS: Thiol-dependent recovery of catalytic activity from oxidized protein tyrosine phosphatases. Biochemistry 2013, 52:6412-6423.
62. Sommer D, Fakata KL, Swanson SA, Stemmer PM: Modulation of the phosphatase activity of calcineurin by oxidants and antioxidants in vitro . Eur J Biochem 2000, 267:2312-2322.
63. Tanner JJ, Parsons ZD, Cummings AH, Zhou H, Gates KS: Redox regulation of protein tyrosine phosphatases: structural and chemical aspects. Antioxid Redox Signal 2011, 15:77-97.